Viewing Study NCT03497767


Ignite Creation Date: 2025-12-25 @ 12:44 AM
Ignite Modification Date: 2026-01-07 @ 6:39 PM
Study NCT ID: NCT03497767
Status: COMPLETED
Last Update Posted: 2024-05-31
First Post: 2018-02-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
Sponsor: Trans Tasman Radiation Oncology Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Non Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non Small Cell Lung Cancer (NSCLC) View
None EGFR mutation View
None Osimertinib View
None Stereotactic Radiosurgery View